Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.
Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG. Li J, et al. Among authors: shalhoub v. Bone. 2006 Oct;39(4):754-66. doi: 10.1016/j.bone.2006.03.017. Epub 2006 May 26. Bone. 2006. PMID: 16730481
The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
Padagas J, Colloton M, Shalhoub V, Kostenuik P, Morony S, Munyakazi L, Guo M, Gianneschi D, Shatzen E, Geng Z, Tan HL, Dunstan C, Lacey D, Martin D. Padagas J, et al. Among authors: shalhoub v. Calcif Tissue Int. 2006 Jan;78(1):35-44. doi: 10.1007/s00223-005-0161-1. Epub 2005 Dec 5. Calcif Tissue Int. 2006. PMID: 16362459
Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.
Kostenuik PJ, Ferrari S, Pierroz D, Bouxsein M, Morony S, Warmington KS, Adamu S, Geng Z, Grisanti M, Shalhoub V, Martin S, Biddlecome G, Shimamoto G, Boone T, Shen V, Lacey D. Kostenuik PJ, et al. Among authors: shalhoub v. J Bone Miner Res. 2007 Oct;22(10):1534-47. doi: 10.1359/jbmr.070616. J Bone Miner Res. 2007. PMID: 17576164 Free article.
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. Li X, et al. Among authors: shalhoub v. J Bone Miner Res. 2009 Apr;24(4):578-88. doi: 10.1359/jbmr.081206. J Bone Miner Res. 2009. PMID: 19049336 Free article.
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Lacey DL, et al. Among authors: shalhoub v. Cell. 1998 Apr 17;93(2):165-76. doi: 10.1016/s0092-8674(00)81569-x. Cell. 1998. PMID: 9568710 Free article.
Characterization of osteoclast precursors in human blood.
Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E, Shimamoto G, Beck J, Kaufman SA, Van G, Scully S, Qi M, Grisanti M, Dunstan C, Boyle WJ, Lacey DL. Shalhoub V, et al. Br J Haematol. 2000 Nov;111(2):501-12. doi: 10.1046/j.1365-2141.2000.02379.x. Br J Haematol. 2000. PMID: 11122091 Free article.
55 results